Condition: Solid Tumor Malignancies · Sponsor: Kumquat Biosciences Inc.
The goal of this trial is to learn if KQB548 works to treat patients with advanced solid malignancies with a KRAS G12D mutation. It will also learn about the safety of KQB548. The main questions it aims to answer are: * What is the safe dose of KQB548? * Does KQB548 decrease the size of the tumor? * What happens to KQB548 in the body?
This description comes directly from the study's public registry record.
Kumquat Clinical Development · 858-214-2700 · kumquatstudies@kumquatbio.com
Always discuss trial participation with your own doctor first.
| University of California, San Diego | La Jolla, California, United States | Recruiting |
| University of California, Los Angeles | Los Angeles, California, United States | Recruiting |
| SCRI - Denver | Denver, Colorado, United States | Recruiting |
| University of Miami - Sylvester Comprehensive Cancer Center | Miami, Florida, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| The Christ Hospital | Cincinnati, Ohio, United States | Recruiting |
| NEXT Oncology - Austin | Austin, Texas, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| NEXT Oncology - Dallas | Irving, Texas, United States | Recruiting |
| NEXT Oncology - San Antonio | San Antonio, Texas, United States | Recruiting |
| University of Utah - Huntsman Cancer Institute | Salt Lake City, Utah, United States | Recruiting |
| NEXT Virginia | Fairfax, Virginia, United States | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07207707